Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Definium Therapeutics Q3 2026 Results: Net Loss of $51M, Loss Narrows

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based treatments like DT120 (LSD) and DT402 (MDMA) for psychiatric disorders. As of November 2, 2026, the company had 136,899,935 common shares outstanding and is currently conducting Phase 3 clinical programs for generalized anxiety disorder and major depressive disorder.

Watch the Definium Therapeutics, Inc. earnings callFull call on the ALFA USA YouTube channel
Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-51.0-67.3
EPS (diluted, $ a share)$-0.46$-0.78

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: DFTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Definium Therapeutics, Inc.: key numbers

Share price
$29.38Close, Nov 17
Market cap
$4.02B
Shares outstanding
136.9MLatest SEC cover page
Sector
Life Sciences
Industry
Medicinal Chemicals & Botanical ProductsSIC 2833

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Definium Therapeutics, Inc.

All →
4:11 PM ET 8-K
Financial Results

Definium Therapeutics Financial Results

Definium Therapeutics reported Q3 2026 financial results, highlighting a strong cash position of $1.05 billion. The company achieved positive Phase 3 topline results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for the same candidate in major depressive disorder.

Term
Q3 2026

“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”

Rob Barrow, Chief Executive Officer

“With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization. Beyond DT120, we believe DT402 represents an exciting opportunity and its initial results support continued development as we work to deliver differentiated therapies for patients with significant unmet needs.”

Rob Barrow, Chief Executive Officer
2:20 AM ET Form 4
Insider Selling

Definium Therapeutics CFO Brandi Roberts Sells $123K of Stock

Brandi Roberts, CFO, sold 3,377 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $123K in total on Sep 25, 2026. Shares held after the trade: 394,528 (-0.8%).

Value
$123K
Shares
3,377
Price
$36.57
Role
CFO
Holding change
-0.8%
Trade date
Sep 25, 2026
2:20 AM ET Form 4
Insider Selling

Definium Therapeutics CLO Mark Sullivan Sells $514K of Stock

Mark Sullivan, CLO, sold 14,051 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $514K in total on Sep 25, 2026. Shares held after the trade: 494,228 (-2.8%).

Value
$514K
Shares
14,051
Price
$36.57
Role
CLO
Holding change
-2.8%
Trade date
Sep 25, 2026
2:20 AM ET Form 4
Insider Selling

Definium Therapeutics Chief Commercial Officer Matthew T. Wiley Sells $113K of Stock

Matthew T. Wiley, Chief Commercial Officer, sold 3,097 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $113K in total on Sep 25, 2026. Shares held after the trade: 359,036 (-0.9%).

Value
$113K
Shares
3,097
Price
$36.57
Role
Chief Commercial Officer
Holding change
-0.9%
Trade date
Sep 25, 2026
2:20 AM ET Form 4
Insider Selling

Definium Therapeutics CEO Robert Barrow Sells $1.15M of Stock

Robert Barrow, CEO, sold 31,550 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $1.15M in total on Sep 25, 2026. Shares held after the trade: 2,213,090 (-1.4%).

Value
$1.15M
Shares
31,550
Price
$36.57
Role
CEO
Holding change
-1.4%
Trade date
Sep 25, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.